ArticleOncoimmunology

Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma.

Abhishek D Garg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.